At a glance
What is it—and why does it matter?
Livagen is identified as a tetrapeptide (KEDA) with the amino-acid sequence Lys-Glu-Asp-Ala. In the small intestine, peptide hydrolases are stated not to hydrolyze Livagen even minimally, implying resistance to enzymatic hydrolysis by these enzymes.
Sources for this introduction: [1] [2]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
Identity
Livagen is described as a synthetic (chemically produced) peptide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“We studied the effects of the synthetic peptide Livagen”
Effects of Livagen peptide on chromatin activation in lymphocytes from old people. · Abstract
pubmed:12533768:6af3ec42591c:6af3ec42591c
Identity
Livagen is identified as the peptide Lys-Glu-Asp-Ala and is described as weakly hydrolyzed.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“It is stated that Livagen (Lys-Glu-Asp-Ala) is a weakly hydrolyzed peptide.”
[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]. · Abstract
pubmed:16075683:2a954726fd51:2a954726fd51
Identity
Livagen is a tetrapeptide with the sequence Lys-Glu-Asp-Ala.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Livagen (Lys-Glu-Asp-Ala)”
[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. · Abstract
pubmed:12942748:c0ddeeb2daf8:c0ddeeb2daf8
Identity
Livagen is identified as a tetrapeptide (KEDA) with the amino-acid sequence Lys-Glu-Asp-Ala.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“KEDA tetrapeptide (Lys-Glu-Asp-Ala, Livagen)”
[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.]. · Abstract
pubmed:32362099:a42efd49eca1:a42efd49eca1
How does it work?
Target, response, and disposition.
Mechanism
In the small intestine, peptide hydrolases are stated not to hydrolyze Livagen even minimally, implying resistance to enzymatic hydrolysis by these enzymes.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Peptide hydrolases of small intestine do not hydrolyze Livagen even to a small extent.”
[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]. · Abstract
pubmed:16075683:2a954726fd51:2a954726fd51
What has been studied?
What the evidence says.
Study findings
In an in vitro assay using human serum, Livagen inhibited enkephalin-degrading enzyme activity (enkephalinase activity).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Livagen and Epitalon inhibited enkephalin-degrading enzymes from human serum.”
[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. · Abstract
pubmed:12942748:c0ddeeb2daf8:c0ddeeb2daf8
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, interaction, regulatory, safety
- 16 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (12), assurance_score_below_0.72 (4), current_regulatory_source_required (2), extraction_ambiguity (16), high_risk_requires_regulatory_or_two_independent_sources (4), no_direct_support (16)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- Effects of Livagen peptide on chromatin activation in lymphocytes from old people. ↗
pubmed · published 2002-10-01 · retrieved 2026-09-08T21:50:40Z
- [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. ↗
pubmed · published 2003-01-01 · retrieved 2026-09-04T22:09:25Z
- [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]. ↗
pubmed · published 2005-01-01 · retrieved 2026-09-09T18:02:46Z
- [The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.]. ↗
pubmed · published 2020-01-01 · retrieved 2026-09-09T22:12:31Z
Publication history and provenance
Version 2 · Automated assessment · 2026-09-09T22:12:31Z
0d7b29bba80f137ad64b63588e047882f151c80673cc4b9daf551e4db57131be